Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00034216 · ClinicalTrials.gov registry record
Collection of Blood From Patients With Cancer
A clinical trial of Breast Cancer and Prostate Cancer, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- 1,750
- Enrollment target
- 1
- Study location
NCT00034216: Recruiting study of Breast Cancer and Prostate Cancer, sponsored by National Cancer Institute (NCI).
NCT00034216 is a study of Breast Cancer and Prostate Cancer that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 1,750 participants, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (38% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00034216, a study of Breast Cancer and Prostate Cancer, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- 1,750 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate. This study does not involve treatment. Participants will have about 50 ml (3 tablespoonfuls) of blood drawn. Depending on their condition, patients may be invited to enroll in a clinical research study involving chemotherapy, radiotherapy, or surgery. Additional 40-ml blood samples may be drawn during the course of treatment. ...
Primary Outcome
Undertake genetic analysis of both prokaryotic and eukaryotic samples for advanced mutational analysis.
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,750 participants |
| Start Date | 2002-07-16 |
What NCT00034216 shows while recruiting
NCT00034216 is an observational study that tracks outcomes without assigning an intervention. Its 1,750 participants enrollment target places it among the larger protocols in the corpus, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (38% lower).
The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT00034216 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00034216 about?
NCT00034216 is a clinical study titled "Collection of Blood From Patients With Cancer". This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate. This study does not involve treatment. Participants will have abou...
What is the current status of trial NCT00034216?
This trial is currently recruiting. The enrollment target is 1,750 participants. The study started on 2002-07-16.
What conditions does trial NCT00034216 study?
This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Lung Cancer, Colon Cancer, Liver Cancer.
Who is sponsoring clinical trial NCT00034216?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00034216 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00034216's enrollment target sits among peer trials
1,750 77th of 1224 higher than 1,147 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05934487 · 1,750 participants · NA
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
- NCT07183527 · 1,750 participants · NA
Hybrid Type I Effectiveness-implementation Cluster Randomized Controlled Trial of CARES
- NCT07062172 · 1,753 participants · NA
Lung Cancer Screening of Family Members of Patients With Mutation-Driven Lung Cancer
- NCT06872892 · 1,755 participants · Phase 3
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI